MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MediWound Ltd. reported second quarter 2026 financial results, highlighting progress in its EscharEx® Phase III VALUE trial targeting chronic wounds and a strengthened commercial agreement with Vericel under a BARDA contract for its burn treatment product NexoBrid®. Revenue for Q2 2026 was $3.1 million, with full-year guidance reaffirmed at $24-26 …